SCHEMBL1944290

SCHEMBL1944290

Cc1cc2c(cc1F)oc(=O)n2C1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.53
CHRM4 P08173 1/20 0.53
CHRM5 P08912 1/20 0.53
CHRM1 P11229 1/20 0.53
CHRM3 P20309 1/20 0.53
HSD11B1 P28845 1/20 0.43
TP53 P04637 1/20 0.42
THRB P10828 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.42
DPP4 P27487 1/20 0.41
GPR119 Q8TDV5 8/20 0.41
PIK3CA P42336 1/20 0.41
MTOR P42345 1/20 0.41
PRKDC P78527 1/20 0.41
SCN9A Q15858 1/20 0.40
USP30 Q70CQ3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3653203 0.83 CHRM2 (0.53) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL2606334 0.79 HSD11B1 (0.57) CHRM4CHRM5CHRM1HSD11B1KDM4E
SCHEMBL4645974 0.79 CHRM1 (0.59) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL2223654 0.78 CHRM2 (0.54) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL1942778 0.77 CHRM2 (0.54) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL24793704 0.76 ASAH1 (0.48) HSD11B1TP53THRBKDM4EMAPT
SCHEMBL3390308 0.74 KDM4E (0.45) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL17096818 0.73 TNKS (0.40) HSD11B1GPR119PIK3CA
SCHEMBL1945607 0.72 CHRM4 (0.72) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL8256058 0.72 GPR119 (0.50) KDM4EGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8344000-B2 Compounds which have activity at M1 receptor and their uses in medicine GLAXO GROUP LIMITED (GB) 2013-01-01 US disclosed
US-8344000-B2 Compounds which have activity at M1 receptor and their uses in medicine GLAXO GROUP LIMITED (GB) 2013-01-01 US disclosed
US-8344000-B2 Compounds which have activity at M1 receptor and their uses in medicine GLAXO GROUP LIMITED (GB) 2013-01-01 US disclosed
US-20110130423-A1 Compounds Which Have Activity At M1 Receptor And Their Uses In Medicine GLAXO GROUP LIMITED, 2011-06-02 US disclosed
US-20110130423-A1 Compounds Which Have Activity At M1 Receptor And Their Uses In Medicine GLAXO GROUP LIMITED, 2011-06-02 US disclosed
US-20110130423-A1 Compounds Which Have Activity At M1 Receptor And Their Uses In Medicine GLAXO GROUP LIMITED, 2011-06-02 US disclosed
EP-2197441-A1 COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE Glaxo Group Limited (GB) 2010-06-23 EP disclosed
WO-2009037293-A1 COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE GLAXO GROUP LIMITED (GB) 2009-03-26 WO disclosed
WO-2009037293-A1 COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE GLAXO GROUP LIMITED (GB) 2009-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130423-A1 Compounds Which Have Activity At M1 Receptor And Their Uses In Medicine CHRM1, CHRM2, CHRM5 CHRM2 2/4885CHRM4 4/4885CHRM5 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.